ORYZON continues to strengthen its patent portfolio for vafidemstat

Oryzon Genomics, S.A.,a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the Russian Patent Office has issued a “Decision to grant” communication for Oryzon’s Russian patent application RU2021130172, titled “Methods of treating borderline personality disorder”. This patent relates to vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for the treatment of psychiatric disorders, including borderline personality disorder (BPD) and schizophrenia.

The “Decision to grant” is a formal communication from the Russian Patent Office indicating that the patent application has reached the stage where it is allowed for issuance as a patent. Once granted, this Russianpatent will not expire until at least 2040, excluding any potential patent term extension, which could provide additional years of protection. Oryzon has also received “Decision to grant” communications forcorresponding patent applications in Europe and Mexico, and a patent has already been granted in Japan. Patent applications are also pending in other relevant markets. 

Additionally, Oryzon recently secured granted patents in Europe, Australia, Korea, Malaysia, and Russiaunder another patent family that covers the use of vafidemstat for the treatment of aggression and social withdrawal. Patent applications in additional countries are pending. These patents will not expire until at least 2038, excluding any potential patent term extensions.

“We are pleased with the continued progress of our global patent strategy for vafidemstat,” said Neus Virgili, Oryzon’s Chief IP Officer. “The issuance of these patents, including the recent “Decision to grant” in Russia, strengthens vafidemstat’s patent portfolio and will significantly extend its commercial lifespan.”